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The list of cancer markers of current interest has grown considerably, but none of the markers used in clinical work is a true tumor marker.
These cancer biomarkers are based on the determination of tumor antigens. Here, we report a single method of autoantibody enzyme immunoassay
(EIA) screens for a spectrum of serum tumor markers. A comparison of the autoantibody-based EIA to conventional antigen EIA kits, using
receiver operating characteristic (ROC) plots, showed that the autoantibody EIA can significantly enhance the sensitivity and specificity of tumor
markers. The detection of serum autoantibodies for a spectrum of serum tumor markers, as demonstrated here, suggests that most, if not all, serum
cancer biomarkers produce autoantibodies. A unique autoantibody biomarker screening method, as presented here, might therefore facilitate achieving
the accurate and early diagnosis of cancer.
Published by Elsevier B.V.Keywords: Extracellular protein kinase A; Autoantibody; Cancer biomarker; Cancer diagnosis; Enzyme immunoassayAn ideal tumor marker would allow a simple blood test to
detect cancer, and its levels would correlate with the stage of
tumor progression. Due to the lack of sensitivity and specificity,
however, no single marker has been recognized as a true cancer
marker [1,2]. Currently, available cancer markers measure can-
cer antigens. For example, the prostate-specific antigen (PSA) is
measured for prostate cancer marker [3], the Carcino-Embryonic
Antigen (CEA) for colorectal cancer [4], the cancer antigen
CA15-3 for breast cancer [5], the cancer antigen CA19-9, for
gastrointestinal cancer [6], and the cancer antigen CA125 for the
diagnosis of ovarian cancer [7].
In addition to the above-mentioned novel markers, some other
proteins, hormones, and enzymes have been used as markers for
the past 30 years [2,8]. Notable among these are α-fetoprotein
(AFP), a liver cancer marker; human chorionic gonadotropin
(hCG), a breast cancer marker; and prostatic acid phosphatase
(PAP), a prostate cancer marker. These markers lack specificity,
however. Their levels are also increased under benign conditions
and during gestation. All these markers are based on the antigen
determination method and lack specificity and sensitivity. There⁎ Corresponding author. Tel.: +1 301 496 4020; fax: +1 301 480 8587.
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doi:10.1016/j.bbadis.2005.12.010is great need to discover novel biomarkers and translate them into
routine clinical use. Our present study is directed to this need.
In normal mammalian cells, two types of cAMP-dependent
protein kinase (PKA) species are present strictly intracellularly
[9]. These protein kinases are designated type I (PKA-I) and type
II (PKA-II); they are distinguished by different regulatory
subunits (R subunits) RI and RII, but they contain a common
catalytic subunit (C subunit) [10]. The ratios of PKA-I to PKA-II
change dramatically during cell development, differentiation,
and transformation [11]. In cancer cells of various cell types,
however, PKA has been shown to be secreted into the con-
ditioned medium [12,13]. This PKA, designated as extracellular
PKA (ECPKA), is shown to be the catalytic subunit (C subunit)
of PKA [12]. Its activity is specifically inhibited [12,13] by the
PKA inhibitor protein, PKI [14], and uses the PKA-specific
substrate, kemptide [12,13]. In cancer cells, the ECPKA expres-
sion has been modulated by changing the ratios of the intra-
cellular type I PKA (PKA-I) to type II (PKA-II) [12], and down-
regulation of ECPKA was shown by a mutant Cα lacking the
N-terminal myristyl group [12]. In the serum of cancer patients,
ECPKA expression is markedly up-regulated, in contrast to
normal serum [12,13], and a surgical removal of melanoma led
to a decrease in ECPKA levels in patients [15].
Fig. 2. Titers of ECPKA autoantibodies in sera from cancer patients with various
cancer cell types and normal control group. Enzyme immunoassay (EIA): Anti-
Ecpka IgG autoantibodies were measured by solid-phase EIA. The plates were
coated with 100 μl of diluted antigen (2 μg per ml PBS) purified recombinant
human PKA Cα subunit at room temperature overnight, and washed once with
washing buffer (20 mM HEPES, 0.9% NaCl, 30 mM sucrose, 0.1% bovine
serum albumin [BSA], pH 7.0), blocked for 2 h at room temperature with 100 μl
of Blockace (Serotec, http://www.serotec.com), and washed two times with Na-
Citrate washing solution (50 mM Na-Citrate, 0.15 M NaCl, 0.1% Tween® 20,
pH 5.0–5.2). We then added 100 μl of 25,000-fold diluted serum samples
(dilution buffer: PBS pH 7.4, 0.25% BSA, 0.05% Tween 20), incubated for
1 h at 37 °C. After three washes with the Na-Citrate solution, added 100 μl
of 20,000-fold diluted anti-human IgG-HRP antibody-enzyme conjugate
(Jackson ImmunoResearch Laboratories, West Grove, PA), in PBS, 0.9%
NaCl, 1% BSA, incubated the samples for 1 h at room temperature, washed five
times in Na-Citrate solution, and added 100 μl of TMB substrate. The reaction
was stopped with 100 μl of 0.45M H2SO4 reagent and the absorbance at 450 nm
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duction of serum autoantibodies and that the presence of such
autoantibodies could serve as a cancer diagnostic. In order to
examine whether ECPKA induces its autoantibody in patients'
sera, we developed a novel enzyme immunoassay (EIA) method
(Fig. 1) to measure the anti-IgG autoantibody for ECPKA. Fig. 2
shows the data obtained from this ECPKA-autoantibody EIA. It
shows the presence of ECPKA autoantibody in the sera of
patients with a wide variety of types of cancers. We tested 345
serum samples from cancer patients. The cancers included breast
(n=24), cervical (n=13), colon (n=40), lung (n=6), ovarian
(n=36), prostate (n=35), pancreatic (n=6), renal cell (n=60),
and rectal (n=14) carcinomas and melanomas (n=90), other
carcinomas (n=19), including bladder, esophageal, gastric,
hepatocellular, and small bowel; and sarcoma, thymoma, lipo-
sarcoma, and leiomyosarcoma. As controls, we used normal sera
from a blood bank (n=163). The serum samples were aliquoted
(5 μl volume) and kept frozen at −80 °C until use. The serum
samples were thawed only once before use. Diluted serum
samples were never used twice. For statistical analysis, mean, S.
D., and confidence intervals (CIs) were used where appropriate.
Data on reproducibility of EIA tests were analyzed by CV at
relevant concentrations and during appropriate temporal inter-
vals; and measures of intraobserver or interobserver variability.
The difference between groups (patients vs. controls) was cal-
culated to have significance at Pb0.05. The results (antibody
titer) were evaluated using receiver operating characteristic
(ROC) [16] plots to determine the optimal sensitivity and spe-
cificity of EIA (see Fig. 3). The assay was reproducible, withFig. 1. Schematic illustration of EIA to detect autoantibodies specific to serum
tumor markers. Ag=antigen; Ab=antibody; E=enzyme. See detailed informa-
tion in the legend of Fig. 2.
recorded on an ELISA reader (BioRad [Hercules, CA] microplate reader
benchmark). Purification of PKA Cα: the recombinant human PKA Cα (1.1 kb)
from OT1529-Cα plasmid [12] was infused with pQE31 DNA leading to
production of pQE-Cα (Hong, S.H. Seoul National University, Seoul, Korea).
pQE-Cα plasmid was expressed in Escherichia coli, and purification of native
PKA Cα protein was achieved (Paragon, Baltimore, MD).within-run and between-run CVs of b5.0% and b5.8%,
respectively.
The serum-presence of autoantibody directed against
ECPKA was highly correlated to cancer. Only representative
data from each tumor type and control group are shown in Fig. 2.
Antibody titers are arbitrarily expressed as ratios to the mean
absorbance of the normal control sera. Values N1.3 (broken line)
were considered positive. High anti-ECPKA, autoantibody titers
(n=345, frequency=90%, mean titer=3.6) were found in cancer
patients, and low or negative titers (n=163, frequency=13%,
mean titer=1.0) were found in the control group (Fig. 2). The
EIA experiments were performed three or more times with each
tumor type consisting of equal numbers of patients and controls
with sample sizes varying 24, 46, and 92. Samples of three
known titers (low, medium, and high) were run in each test to
check for the reproducibility of the assays.
We compared these data with data from a PKA enzymatic
assay that measures antigen [12]. A comparison of individual
anti-ECPKA autoantibody titers obtained by EIA with those
measured by PKA enzymatic assay showed no correlation bet-
ween the two assays. The sensitivity and specificity of auto-
antibody EIA and those of the PKA assay were evaluated using
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a sensitivity of 90% (95% confidence interval, 0.88 to 0.92),
and specificity of 87% (95% confidence interval, 0.80 to 0.95)
(AUC: 0.93675), and the enzymatic assay showed a sensitivity
of 83%, and specificity of 80% (AUC: 0.86938) (Fig. 3a). These
data show that the ECPKA autoantibody-detection method
exhibits a higher sensitivity and specificity than the antigen
detecting method.
We speculated that the known serum tumor markers might
also produce autoantibodies, as was shown for ECPKA, and
that the autoantibody-based EIA developed for ECPKA could
be extended to assay these serum tumor-marker autoantibo-
dies. For comparison, we also assayed the nine serum tumor
markers with their antigen kits, and evaluated the data by
ROC plots (Fig. 3b–j). The autoantibody EIAs of tumor
markers were performed as described above, except for the use
of each specific tumor antigen for coating the EIA plates and
appropriate tumor types. Thus, for AFP, we used serum from
liver, lung, and pancreatic cancer patients; for CA125, serum
from mucinous or nonmucinous ovarian cancer patients; for
VEGF, serum from breast and colon and gastric cancer
patients; for CA15-3, hCG, and HER-2, serum from breast
cancer patients; for CEA and CA19-9, we used colon and
gastric cancer patient's serum; and for PSA, we used prostate
cancer patients' serum. Each EIA consisted of equal numbers
of patients' and control sera. Sample sizes varied, either 24,
46, or 92. Importantly, the same samples assayed by EIA were
also assayed by the antigen kit, usually on the same day. The
autoantibody EIA and antigen kit assays for each tumor
marker were performed with three or more times of repeated
experiments. The mean, S.D., and confidence intervals (CIs)
were used where appropriate. The difference between groups
(patients vs. controls) was calculated to have significance at
Pb0.05. ROC curves were used to calculate the cutoff values
for optimal sensitivity and specificity. These results were
reproducible, with within-run and between-run CVs of b6.0%
and b6.3%, respectively.
This comparison provided a striking difference in the sen-
sitivity and specificity achieved by the autoantibody EIA com-
pared to what the antigen kits of the individual tumor markers
produced for some markers. The liver tumor marker α-fetal
protein (AFP) [8], measured by autoantibody EIA, showed
sensitivity of 89% and specificity of 77% (AUC: 0.84150),
compared to measurements by the AFP antigen kit of 60% and
69%, respectively (AUC: 0.60243) (Fig. 3b). Similarly, the
nonmucinous ovarian cancer antigen CA125 [7], measured by
autoantibody EIA, had sensitivity of 70% and specificity of
83% (AUC: 0.75520), compared to its antigen kit measure-
ments of 45% sensitivity and 70% specificity (AUC: 0.49211)Fig. 3. Receiver operating characteristic (ROC) plots of autoantibody EIA and An
autoantibody EIA and antigen EIA kit for each tumor marker are presented graphica
(red) and those of the anti-ECPKA autoantibody EIA (black). In panels b–j: red=da
serum tumor markers. b, AFP; c, CA125; d, VEGF; e, CA15-3; f, hCG; g, HER-2; h,
CA19-9, and hCG were from Biodesign International (Saco, ME); CEAwas from S
PSAwas from Aspen Bio, Inc. (Castle Rock, CO). The antigen-EIA kits for AFP, PS
Diego, CA); HER-2 was obtained from Sigma-Aldrich (St. Louis, MO); and VEGF w(Fig. 3c). The blood vessel (and thus tumor) growth factor,
vascular endothelial growth factor (VEGF) [17], as measured by
the autoantibody EIA, showed sensitivity of 66% and spe-
cificity of 85% (AUC: 0.84688), compared to 40% sensitivity
and 79% specificity (AUC: 0.54333) when measured by the
antigen kit (Fig. 3d).
By contrast, in the tumor markers for breast cancer, CA15-3
[5], hCG [18], and Her-2 [19], and for colon and gastrointestinal
cancers, CEA [4], and CA19-9 [6], the autoantibody EIA
exhibited sensitivity, specificity, andAUC (see the legend of Fig.
3) similar to those obtained with the antigen kits (Fig. 3e–i).
These results indicate that a single autoantibody EIA method
was applicable for the detection of autoantibodies specific for
each of these nine tumor markers. The parallel results (ROC
curves almost superimposable) obtained by the autoantibody
EIA and antigen kit assay for a given tumor marker, compared to
the distinct ROC curves of these assays obtained for different
tumor markers, support the autoantibody-EIA method presented
here as a universal screen for serum tumor markers.
In the case of PSA [3], however, the autoantibody EIA
exhibited a lower sensitivity and specificity than the antigen-
determining kit (Fig. 3j). Although use of prostate-specific
antigen has been of value in the detection, diagnosis, and clinical
management of men with prostate cancer, problems with spe-
cificity remain. Serum PSA levels not only reflect changes due to
cancer, but also changes due to inflammation, trauma, or benign
proliferation [3]. There is also considerable overlap in PSA
levels among men with prostate cancer and benign disease
despite the discovery of new molecular forms, such as free PSA
(fPSA) and complexed derivatives of PSA that offer the potential
for improved diagnostic discrimination of prostate cancer from
benign conditions [3].
We examined whether PSA autoantibody detection could be
valuable to distinguish prostate cancer patients with androgen-
sensitive (AS) disease from those with androgen-insensitive
(AI) disease. As shown in Fig. 4, the autoantibody EIA clearly
distinguished the AS and AI groups of patients. The AS group
exhibited a high sensitivity (95%) and specificity (75%)
whereas the AI group showed low sensitivity (60%) and spe-
cificity (50%) (Fig. 4). With the PSA-antigen kit, however, there
was no significant distinction between the AS and AI groups in
sensitivity, specificity, or AUC (Fig. 4).
In the present study, we have presented a highly sensitive
EIA for measuring IgG autoantibodies against a spectrum of
serum tumor markers. Using receiver operating characteristic
(ROC) plots, the data obtained with the autoantibody EIAwere
evaluated in comparison to those obtained with antigen-
determination kits. The ROC plots divided the tumor markers
into two groups. In the first group, which included tumortigen EIA kit for serum tumor markers. The sensitivity and specificity of the
lly in an ROC curve. Panel a represents the data of the ECPKA enzymatic assay
ta from antigen-EIA kits; black=data of autoantibody EIA for each designated
CEA; i, CA19-9; and j, PSA. The tumor antigens, AFP, VEGF, CA125, CA15-3,
igma-Aldrich (St. Louis, MO), HER2 was from Invitrogen (Carlsbad, CA); and
A, CEA, hCG, CA 125, CA 19-9, and CA 15-3 were from Bio-Quant, Inc. (San
ere from Assay Designs (Castle Rock, CO). 
Fig. 4. Receiver operating characteristic (ROC) plots of autoantibody EIA and
antigen EIA kit assays in androgen-sensitive (AS) versus androgen-insensitive
(AI) prostate cancers. The ROC curves were plotted as described above.
Black= the autoantibody EIA of androgen-sensitive (AS) prostate cancer, area
under curve (AUC 0.88611); blue= the autoantibody EIA of androgen-
insensitive (AI) prostate cancer (AUC 0.62500); green= the antigen kit assay
of the AS prostate cancer (AUC 0.49286); red= the antigen-kit assay of the AI
prostate cancer (AUC 0.69000). EIA autoantibody experiments were performed
as described in the text on 18 serum samples of AS prostate cancer and 14 serum
samples of AI prostate cancer, with equal numbers of controls for the EIA and
antigen kits.
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EIA showed markedly enhanced sensitivity and specificity
compared to results obtained with the antigen kits. By contrast,
in the second group of markers, including CA15-3, hCG, Her-2,
CEA, CA19-9, and the sensitivity and specificity obtained by
the autoantibody EIA and antigen kits were quite similar. The
ROC curves from the two assays were, in fact, almost super-
imposable (Fig. 3). That this spectrum of serum tumor markers
exhibited super or equivalent sensitivity and specificity to those
obtained with the specific tumor-antigen kits strongly supports
that (1) serum tumor markers may all produce autoantibodies
and (2) the unique autoantibody EIA presented here may open a
new gateway for cancer diagnostics.
The enhancement of sensitivity and specificity of tumor
markers elicited by the autoantibody-EIA could have immediate
clinical significance. For example, VEGF, the vascular en-
dothelial growth factor, has been shown to be a key mediator
of blood vessel growth and thus for tumor growth [17], and
its detection gives valuable information to patients for the
choice of new treatment [20]. CA125, an ovarian tumor marker,
combined with transvaginal ultrasound examination, appears to
provide the highest specificity and positive predictive value for
the detection of ovarian cancer [7]. Patients with the lymph
node-positive and aggressively growing HER-2-positive breast
tumors could receive beneficial effects from treatment with
herceptin (a monoclonal antibody for HER-2) [21].
Importantly, our PSA analysis data comparing androgen-
sensitive (AS) and -insensitive (AI) prostate cancers were the
most striking results (Fig. 4). The high PSA autoantibody
production in AS and the distinctively low PSA autoantibody
production in AI clearly distinguished these two groups, where-as this was not possible using the PSA antigen determination
(kit) (Fig. 4). The data are not only valuable for determination of
therapeutic choice but are also important for monitoring the
progression and prognosis of the disease.
One of the most important criteria for cancer markers is the
ability to distinguish cancer from inflammatory and benign
diseases such as hepatitis, pancreatitis, and benign disease
causing PSA increase. Because known cancer markers all de-
pend on the measurement of cancer antigens, the distinction
between inflammation and cancer is difficult. In the present
study, we used a single EIA method of autoantibody detection.
An increase in cancer biomarkers can occur temporarily with
inflammation [3]; but because such an increase in cancer anti-
gens might not increase autoantibodies, our autoantibody-
detection method could make it possible to distinguish between
the increase in levels of tumor markers caused by cancer and that
caused by inflammation.
Monitoring the quantitative relationship of autoantibody
titers of cancer antigens, such as ECPKA, with disease prog-
ression and prognosis would be of importance, but this is yet to
be accomplished. Autoantibody monitoring of cancer antigens
would also be critically important in the early detection of
relapsing patients. Because ECPKA levels were shown to fall
after surgical removal of melanoma [15], if a patient began to
show re-increase in ECPKA autoantibody that previously
showed a decrease upon surgical removal of a tumor, it could
be an early sign of disease recurrence. Such studies have not yet
been performed.
The protein products of oncogenes and tumor suppressor
genes can be detected in extracellular fluids and serve as po-
tential markers for carcinogenesis in vivo. Antibodies against
p53 tumor suppressor protein were found in the sera of patients
with breast [23] and lung carcinomas [22] and in children with
B-lymphomas [24]. Circulating antibodies against the oncogene
product c-myc was also found in sera of patients with colorectal
cancer [25].
A test based on the demonstration of autoantibodies to tumor
antigen in sera of patients, as described here, could be of great
importance for early diagnosis because of the prolonged time
course of carcinogenesis [26] and the possibility that a very
small tumor or a subtle biochemical change in the cell might be
able to produce a detectable level of anti-stimulant autoantibody
in response to chemical/viral carcinogens, before the emergence
of the tumor phenotype [1]. This could happen well before the
released tumor antigen reaches a detectable level. Our results
thus suggest that the autoantibody detection rather than antigen
detection would serve for early diagnosis.
Our results further indicate the utility of the autoantibody-
based EIA method presented here as a routine diagnostic pro-
cedure to detect cancer of various cell types by measuring var-
ious serum tumor biomarkers with a single assay. Thus, the
autoantibody biomarker-detecting EIA is superior to antigen-
determining kits in time saved for diagnoses, and savings for
patients of the costs of the kits. This new assay, autoantibody
detection, could remove false positives often associated with
conventional testing and provide a novel technology for cancer
detection.
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